Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$7.4 million.

  • BridgeBio Pharma's Change in Account Payables fell 10638.71% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 5333.45%. This contributed to the annual value of $1.5 million for FY2024, which is 4561.15% down from last year.
  • BridgeBio Pharma's Change in Account Payables amounted to -$7.4 million in Q3 2025, which was down 10638.71% from -$1.1 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Change in Account Payables peaked at $17.6 million during Q1 2025, and registered a low of -$11.7 million during Q3 2021.
  • Over the past 5 years, BridgeBio Pharma's median Change in Account Payables value was -$298000.0 (recorded in 2023), while the average stood at $834736.8.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Change in Account Payables was 506140.94% (2024), while the steepest drop was 61887.61% (2024).
  • BridgeBio Pharma's Change in Account Payables (Quarter) stood at $1.5 million in 2021, then decreased by 6.59% to $1.4 million in 2022, then surged by 349.42% to $6.2 million in 2023, then crashed by 160.56% to -$3.7 million in 2024, then tumbled by 98.45% to -$7.4 million in 2025.
  • Its Change in Account Payables was -$7.4 million in Q3 2025, compared to -$1.1 million in Q2 2025 and $17.6 million in Q1 2025.